Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

78 results

Filters applied: . Clear all
Page 1
Is it preferable to administer a bronchodilator once- or twice-daily when treating COPD?
Matera MG, Rinaldi B, Ambrosio C, Cazzola M. Matera MG, et al. Among authors: cazzola m. Respir Med. 2023 Nov-Dec;219:107439. doi: 10.1016/j.rmed.2023.107439. Epub 2023 Oct 24. Respir Med. 2023. PMID: 37879449 Review.
Nocturnal and early morning symptoms are common and uncomfortable in many patients with COPD, and are likely to affect their long-term outcomes. However, it is still debated whether it is better to give long-acting bronchodilators once- or twice-daily to symptomatic COPD p …
Nocturnal and early morning symptoms are common and uncomfortable in many patients with COPD, and are likely to affect their long-term …
Pharmacotherapies in Older Adults with COPD: Challenges and Opportunities.
Matera MG, Hanania NA, Maniscalco M, Cazzola M. Matera MG, et al. Among authors: cazzola m. Drugs Aging. 2023 Jul;40(7):605-619. doi: 10.1007/s40266-023-01038-0. Epub 2023 Jun 14. Drugs Aging. 2023. PMID: 37316689 Free PMC article. Review.
Older adults have a higher prevalence of chronic obstructive pulmonary disease (COPD), which will likely increase substantially in the coming decades owing to aging populations and increased long-term exposure to risk factors for this disease. COPD in older adults is chara …
Older adults have a higher prevalence of chronic obstructive pulmonary disease (COPD), which will likely increase substantially in the comin …
Biologic therapies for chronic obstructive pulmonary disease.
Matera MG, Calzetta L, Cazzola M, Ora J, Rogliani P. Matera MG, et al. Among authors: cazzola m. Expert Opin Biol Ther. 2023 Feb;23(2):163-173. doi: 10.1080/14712598.2022.2160238. Epub 2022 Dec 26. Expert Opin Biol Ther. 2023. PMID: 36527286 Review.
This may reflect the complexity of COPD, in which no single cytokine or chemokine has a dominant role. Because the umbrella term COPD encompasses several endotypes with diverse underlying processes, mAbs targeting specific cytokines or chemokines should most likely be eval …
This may reflect the complexity of COPD, in which no single cytokine or chemokine has a dominant role. Because the umbrella term COPD …
Pharmacotherapy of LAMA/LABA inhaled therapy combinations for chronic obstructive pulmonary disease: a clinical overview.
Matera MG, Rinaldi B, Belardo C, Cazzola M. Matera MG, et al. Among authors: cazzola m. Expert Rev Clin Pharmacol. 2022 Nov;15(11):1269-1281. doi: 10.1080/17512433.2022.2134113. Epub 2022 Nov 2. Expert Rev Clin Pharmacol. 2022. PMID: 36324269 Review.
EXPERT OPINION: The available data supports the use of inhaled LAMA/LABA FDCs in treating COPD patients, particularly those with severe or very severe disease. These combinations provide short - and long-term benefits to COPD patients without increasing the dose of the sin …
EXPERT OPINION: The available data supports the use of inhaled LAMA/LABA FDCs in treating COPD patients, particularly those with severe or v …
Ineffective erythropoiesis and its treatment.
Cazzola M. Cazzola M. Blood. 2022 Apr 21;139(16):2460-2470. doi: 10.1182/blood.2021011045. Blood. 2022. PMID: 34932791 Free article.
Luspatercept is also approved for the treatment of transfusion-dependent anemia in patients with MDS with ring sideroblasts, most of whom carry a somatic SF3B1 mutation. While the long-term effectiveness and safety of luspatercept need to be evaluated in beta-thalassemia a …
Luspatercept is also approved for the treatment of transfusion-dependent anemia in patients with MDS with ring sideroblasts, most of whom ca …
Rationale and Clinical Use of Bronchodilators in Adults with Bronchiectasis.
Martínez-García MÁ, Oscullo G, García-Ortega A, Matera MG, Rogliani P, Cazzola M. Martínez-García MÁ, et al. Among authors: cazzola m. Drugs. 2022 Jan;82(1):1-13. doi: 10.1007/s40265-021-01646-3. Epub 2021 Nov 26. Drugs. 2022. PMID: 34826104
We performed a systematic review of the literature and were able to verify that there are no randomised controlled trials (apart from a small study with methodological limitations and a very recent trial involving a not-very-large number of patients), or any long-term obse …
We performed a systematic review of the literature and were able to verify that there are no randomised controlled trials (apart from a smal …
Preexisting cardiorespiratory comorbidity does not preclude the success of multidisciplinary rehabilitation in post-COVID-19 patients.
Maniscalco M, Fuschillo S, Ambrosino P, Martucci M, Papa A, Matera MG, Cazzola M. Maniscalco M, et al. Among authors: cazzola m. Respir Med. 2021 Aug;184:106470. doi: 10.1016/j.rmed.2021.106470. Epub 2021 May 15. Respir Med. 2021. PMID: 34022502 Free PMC article.
Patients recovering from coronavirus disease 2019 (COVID-19) may not return to a pre-COVID functional status and baseline levels of healthcare needs after discharge from acute care hospitals. Since the long-term outcomes of COVID-19 can be more severe in patients with unde …
Patients recovering from coronavirus disease 2019 (COVID-19) may not return to a pre-COVID functional status and baseline levels of healthca …
The mechanical and chemical stability of the interfaces in bioactive materials: The substrate-bioactive surface layer and hydroxyapatite-bioactive surface layer interfaces.
Ferraris S, Yamaguchi S, Barbani N, Cristallini C, Gautier di Confiengo G, Barberi J, Cazzola M, Miola M, Vernè E, Spriano S. Ferraris S, et al. Among authors: cazzola m. Mater Sci Eng C Mater Biol Appl. 2020 Nov;116:111238. doi: 10.1016/j.msec.2020.111238. Epub 2020 Jun 25. Mater Sci Eng C Mater Biol Appl. 2020. PMID: 32806332 Free article.
In the present research, five different bioactive materials (a bioactive glass and four different chemically treated bioactive titanium surfaces) have been studied and compared in terms of mechanical stability of the surface bioactive layer-substrate interface, their long term …
In the present research, five different bioactive materials (a bioactive glass and four different chemically treated bioactive titanium surf …
Pharmacological management of COVID-19 patients with ARDS (CARDS): A narrative review.
Matera MG, Rogliani P, Calzetta L, Cazzola M. Matera MG, et al. Among authors: cazzola m. Respir Med. 2020 Sep;171:106114. doi: 10.1016/j.rmed.2020.106114. Epub 2020 Aug 4. Respir Med. 2020. PMID: 32795902 Free PMC article. Review.
Unfortunately, there is still no definite drug for CARDS that is capable of reducing either short-term or long-term mortality and no specific treatments for COVID-19 exist right now. ...
Unfortunately, there is still no definite drug for CARDS that is capable of reducing either short-term or long-term mortality …
Pharmacological management of adult patients with acute respiratory distress syndrome.
Matera MG, Rogliani P, Bianco A, Cazzola M. Matera MG, et al. Among authors: cazzola m. Expert Opin Pharmacother. 2020 Dec;21(17):2169-2183. doi: 10.1080/14656566.2020.1801636. Epub 2020 Aug 12. Expert Opin Pharmacother. 2020. PMID: 32783481 Review.
INTRODUCTION: There is still no definite drug for acute respiratory distress syndrome (ARDS) that is capable of reducing either short-term or long-term mortality. Therefore, great efforts are being made to identify a pharmacological approach that can be really effec …
INTRODUCTION: There is still no definite drug for acute respiratory distress syndrome (ARDS) that is capable of reducing either short-ter …
78 results